Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.39 |
| ▸ | HTR2C | P28335 | 3/20 | 0.39 |
| ▸ | HTR2B | P41595 | 3/20 | 0.39 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.33 |
| ▸ | XDH | P47989 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 3/20 | 0.31 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22477050 | 0.83 | KDM4E (0.34) | HTR2AHTR2CHTR2BXDHALDH1A1 | |
| SCHEMBL21360807 | 0.81 | TAAR1 (0.34) | HTR2AHTR2CHTR2BALDH1A1MAPT | |
| SCHEMBL5512979 | 0.71 | HTR2C (0.53) | HTR2AHTR2CHTR2BACHE | |
| SCHEMBL25196987 | 0.70 | ALDH1A1 (0.41) | PDE7AXDHALDH1A1GRIN1GRIN2A | |
| SCHEMBL30047417 | 0.70 | ALDH1A1 (0.41) | PDE7AXDHALDH1A1GRIN1GRIN2A | |
| SCHEMBL21360735 | 0.69 | ERN1 (0.38) | HTR2AHTR2CHTR2BALDH1A1GAA | |
| SCHEMBL6249142 | 0.68 | HTR2C (0.51) | HTR2AHTR2CHTR2BALDH1A1MAPT | |
| SCHEMBL21360741 | 0.67 | TAAR1 (0.36) | HTR2AHTR2CHTR2BGAA | |
| SCHEMBL5951317 | 0.67 | ACHE (0.54) | ALDH1A1MAPTACHEMAPK14 | |
| SCHEMBL9571076 | 0.66 | HTR2C (0.47) | HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3401306-B1 | DEZOCINE ANALOGUE | SHANDONG DANHONG PHARMACEUTICAL CO LTD (CN) | 2020-09-30 | — | — | EP | disclosed |
| US-10414718-B2 | Dezocine analogue | SHANDONG DANHONG PHARMACEUTICAL CO., LTD. (CN) | 2019-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10414718-B2 | Dezocine analogue | DDO, DDC, DAO | HTR2A 110/4885HTR2C 76/4885HTR2B 487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.